Mr. Chris Dallin reports

ASEP MEDICAL ANNOUNCES $1,056,872 DEBT SETTLEMENT

ASEP Medical Holdings Inc. intends to settle debt, on March 26, 2026, in the aggregate amount of $1,056,872 owed by the company to certain creditors of the company in exchange for 4,489,614 common shares at a price of 24 cents per settlement share. The debt to be settled relates to fees payable to certain creditors, directors, officers and advisers of the company.

The proposed debt settlement is a related-party transaction within the meaning of Multilateral Instrument 61-101 (Protection of Minority Security Holders in Special Transactions). The debt settlement is exempt from the valuation requirement of MI 61-101 by virtue of the exemptions contained in Section 5.5(b) of MI 61-101 as the common shares are not listed on a specified market and from the minority shareholder approval requirements of MI 61-101 by virtue of the exemption contained in Section 5.7(1)(a) of MI 61-101 in that the fair market value of the debt settlement will not exceed 25 per cent of the company's market capitalization. As the material change report disclosing the debt settlement is being filed fewer than 21 days before the transaction, there is a requirement under MI 61-101 to explain why the shorter period was reasonable or necessary in the circumstances. In the view of the company, it is necessary to immediately close the debt settlement, and, therefore, such shorter period is reasonable and necessary in the circumstances to improve the company's financial position.

About ASEP Medical Holdings Inc.

ASEP Medical is a standout biotechnology research and development company based in Victoria, B.C., Canada. The company possesses a valuable portfolio of global patents for innovative diagnostic and therapeutic medical technologies. These technologies were developed over the past decade at the University of British Columbia under the guidance of Dr. Robert E.W. Hancock, one of the world's foremost microbiologists. ASEP holds a controlling interest in two private subsidiary companies: Sepset Biosciences (ASEP's leading product, a sepsis diagnostic technology) and ABT Innovations (specializing in anti-biofilm technology). As the company's patented innovations address unmet medical needs, it presents a unique investment opportunity for both retail and institutional investors.

We seek Safe Harbor.